ERBB2 and neoplasm: The pCR rate was 9.7% (three out of 32) in oestrogen receptor-positive and 25% (two out of eight) in oestrogen receptor-negative tumours, 17.4% (four out of 23) in Mib-1 ⩾20 and 7.7% (one out of 13) in Mib-1 <20% tumours, 20% (one out of five) and 4% (one out of 25) in Her-2-positive and -negative tumours, respectively; none of these differences reached statistical significance.